MicroVention, Inc.

microvention is a rapidly growing medical device company that has pioneered the development of catheter-based, minimally invasive, neuroendovascular technologies that provide therapeutic advantages for neurovascular disorders. since the launch of their first generation hydrocoil™ embolic system in 2003, microvention has expanded its portfolio to every corner of the neuroendovascular industry—now producing best-in-class embolic coils, intrasaccular devices, coil-assist stents, and flow diverters. with the celebration of their 3rd fda premarket approval (pma) in an 18-month timeframe, microvention now holds more pma’s than any other company in their industry as of january 2020. headquartered in the sunny southern california city of aliso viejo, california, microvention is a short distance from beaches, mountains, and hiking trails. associates enjoy a positive work-life balance with perks like an on-site fitness center, continuing education programs, community service opportunities, talent development, and much more. our company is filled with incredible team players that collaborate, are innovative, and are motivated daily to develop the best-in-class neuroendovascular devices. in 2022, microvention was certified in the u.s. and in costa rica as a great place to work by great places to work; the global authority on workplace culture. our incredible associates are the ones that make this a great place to work! microvention is committed to developing and manufacturing the highest quality products for customers and patients while maintaining a strong clinical research and r&d focus to respond quickly to customer needs and advance therapeutic modalities. microvention is dedicated to the development and commercialization of innovative endovascular technologies that provide a meaningful improvement in patient lives. innovation starts with you! see more at http://www.microvention.com

Trova indirizzi email

Provatelo velocemente con tomba.io. tomba.io.

Trova indirizzi email da un elencoInizia con Google